home / stock / caba / caba quote
Last: | $ |
---|---|
Change Percent: | -1.04% |
Open: | $15.50 |
Close: | $15.26 |
High: | $15.79 |
Low: | $14.94 |
Volume: | 23,636 |
Last Trade Date Time: | 02/12/2020 04:43:39 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $15.50 | $15.26 | $15.79 | $14.94 | 23,636 | 02-12-2020 |
$ | $15.04 | $15.42 | $15.79 | $14.88 | 33,399 | 02-11-2020 |
$ | $15.39 | $15.05 | $15.89 | $14.88 | 26,717 | 02-10-2020 |
$ | $16.36 | $15.46 | $16.36 | $15.16 | 56,344 | 02-07-2020 |
$ | $16.02 | $16.45 | $16.67 | $15.25 | 56,164 | 02-06-2020 |
$ | $15.30 | $15.94 | $15.94 | $15.16 | 40,603 | 02-05-2020 |
$ | $15.45 | $15.28 | $15.8299 | $15.06 | 36,110 | 02-04-2020 |
$ | $16.82 | $15.59 | $16.87 | $15.00 | 124,238 | 02-03-2020 |
$ | $16.93 | $16.43 | $17.70 | $16.27 | 28,963 | 01-31-2020 |
$ | $18.54 | $17.12 | $18.54 | $16.80 | 44,075 | 01-30-2020 |
$ | $16.52 | $18.67 | $19.63 | $16.52 | 97,965 | 01-29-2020 |
$ | $17.66 | $16.46 | $17.80 | $16.26 | 43,446 | 01-28-2020 |
$ | $17.47 | $17.63 | $18.00 | $17.47 | 77,333 | 01-27-2020 |
$ | $17.22 | $17.47 | $17.99 | $17.12 | 53,874 | 01-24-2020 |
$ | $16.35 | $17.15 | $17.7881 | $16.07 | 94,477 | 01-23-2020 |
$ | $16.23 | $16.37 | $17.1038 | $15.96 | 49,468 | 01-22-2020 |
$ | $16.28 | $16.17 | $16.625 | $15.90 | 51,014 | 01-21-2020 |
$ | $16.39 | $16.37 | $17.13 | $15.84 | 100,578 | 01-20-2020 |
$ | $16.39 | $16.37 | $17.13 | $15.84 | 100,578 | 01-17-2020 |
$ | $16.07 | $16.27 | $16.7755 | $15.62 | 81,419 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...